Venlafaxine: the legal and safety record

The Class I recall — the only one in this library

Every other page in this series reports the same verified negative: no Class I recall on record. Venlafaxine is the exception, so it gets the same precision. In March 2014, a pharmacist opened a sealed bottle of Effexor XR 150 mg and found one capsule that didn’t belong: peach-colored, printed TKN250 — Tikosyn (dofetilide), an antiarrhythmic dosed in micrograms precisely because getting it wrong can trigger fatal heart rhythms. Pfizer recalled the associated lots; the FDA classified the recall Class I — the category reserved for reasonable probability of serious harm or death [1]. Scope, stated exactly: one foreign capsule found, a precautionary recall of the lots that could share the packaging line — not evidence the supply was contaminated. Both the severity and the narrowness are the record.

The two-year delay, priced

The other Effexor case was never about the molecule — it was about the calendar. In 2005 Wyeth and Teva settled a patent fight with an agreed date, July 1, 2010, for generic Effexor XR to launch, and Wyeth promised not to launch its own generic against Teva’s. The original venlafaxine patent had expired in June 2008. Purchasers allege that the deal was a “pay-for-delay” arrangement, so everyone who bought the brand at brand prices in the gap paid the alleged cost [3]. After more than a decade in the District of New Jersey: Wyeth settled the direct-purchaser claims for $39 million (2024) and the indirect-purchaser claims for $25.5 million (2024), and Teva settled the indirect-purchaser claims for $2.25 million, approved in August 2025. Indirect purchasers are the insurers and consumers who ultimately paid for the drug, as opposed to wholesalers. The wholesalers’ case against Teva is still open [2]. The required precision: these are settlements. No court has decided the pay-for-delay claim, and the Wyeth direct-purchaser agreement says in terms that it is not an admission of liability. (An earlier version of this page cited class counsel’s website and a trade-press story, described Pfizer rather than its subsidiary Wyeth as the indirect-purchaser settler, and did not say the case against Teva continues. It now cites the court docket and the Third Circuit’s opinion.) What the case documents either way is who pays for delayed generics: the people refilling the prescription.

The dog that didn’t bark: withdrawal

Ask patient communities which antidepressant is hardest to stop and venlafaxine is reliably near the top; its own label warns about discontinuation symptoms [4]. Yet unlike duloxetine — whose withdrawal litigation filled a page of this series — venlafaxine produced almost no litigated record on the question. The lesson this library keeps relearning: courtroom volume is a terrible proxy for pharmacology. What matters for a person stopping the drug is the taper evidence in the stopping guide, not the docket count.

Common questions

Was Effexor XR really recalled because of a heart drug in the bottle?

Yes — the exact words of the FDA enforcement record: 'Presence of Foreign Tablets/Capsules: A Pharmacist reported that a bottle of Effexor XR 150 mg capsules contained a single peach colored capsule printed TKN250' — a 250-microgram capsule of Tikosyn (dofetilide), an antiarrhythmic whose dosing errors can cause fatal heart rhythms. Pfizer recalled the affected lots in March 2014 and the FDA classified it Class I, the most serious recall category. Scope matters: one foreign capsule found, a precautionary recall of the associated lots — not evidence of widespread contamination.

What was the Effexor antitrust case about?

Purchasers allege that Wyeth (later Pfizer) and Teva's 2005 patent settlement, which set a July 1, 2010 entry date for generic Effexor XR, was an unlawful 'pay-for-delay' deal that kept generics out after the original venlafaxine patent expired in June 2008. After more than a decade in the District of New Jersey, Wyeth settled with direct purchasers (wholesalers and pharmacies) for $39 million (final approval June 2024) and with indirect purchasers (insurers and consumers) for $25.5 million (final approval September 2024); Teva settled with indirect purchasers for $2.25 million (final approval August 2025). The direct purchasers' case against Teva is still being litigated. No court has decided whether the agreement was illegal, and the Wyeth direct-purchaser agreement states that it is not an admission of liability.

Is there a lawsuit about Effexor withdrawal?

Essentially no litigated record, and that absence is worth stating exactly because venlafaxine is one of the drugs most named in the discontinuation literature and in patient communities for difficult stops. Courts are a poor mirror of pharmacology: duloxetine — a similar SNRI — drew years of withdrawal litigation (which the manufacturer largely won), while venlafaxine drew almost none. The evidence about tapering stands on its own, regardless of what was or wasn't filed; our stopping guide covers it.

Does venlafaxine have a black box warning?

Yes — the class-wide antidepressant suicidality warning ordered by the FDA in 2004 and extended to young adults in 2007, same as every drug in this series. No venlafaxine-specific boxed warning exists beyond it.

Considering venlafaxine itself? The venlafaxine page has the approval basis, prescription volumes, and label warnings, sourced the same way.

Sources

Last verified 2026-09-29. Corrections change this date.